a Department of Nephrology , The First Affiliated Hospital of Anhui Medical University , Hefei , China.
b Department of Nephrology , The Second Hospital of Anhui Medical University , Hefei , China.
Ren Fail. 2019 Nov;41(1):244-256. doi: 10.1080/0886022X.2019.1595646.
To date, the prevalence and prognostic role of coronary artery calcification (CAC) in patients with chronic kidney disease (CKD) have been investigated in several studies, but have yielded conflicting results. The aim of this meta-analysis is to derive a more precise estimation of CAC prevalence in CKD patients and its association with cardiovascular events and mortality.
The relevant literature was identified and evaluated from inception until July 2018 through multiple search strategies on PubMed, Embase, and Web of Science. Cross-sectional or cohort (baseline data) studies reporting CAC prevalence were included. Data extracted from eligible studies were used to calculate effect estimates (ESs) and 95% confidence intervals (95%CI). We searched databases for observational studies that explored baseline CAC and subsequent cardiovascular or all-cause mortality risk in CKD patients.
The meta-analysis included 47 studies; 38 of these were included in the final analysis of CAC prevalence. The pooled prevalence of CAC in random effect model was 60% (95%CI 53-68%). CAC was positively associated with an increased risk of all-cause mortality (hazard ratio [HR] 3.44; 95%CI 2.40-4.94), cardiovascular mortality (HR 3.87; 95%CI 2.06-7.26), and cardiovascular events (HR 2.09; 95%CI 1.19-3.67), when comparing individuals in the top CAC score group to those in the bottom CAC score group.
The pooled prevalence of CAC is highly prevalent. CAC is independently associated with all-cause and cardiovascular mortality risk as well as cardiovascular events among CKD patients. In view of the high heterogeneity, larger clinical trials are still needed.
迄今为止,已有多项研究调查了慢性肾脏病(CKD)患者冠状动脉钙化(CAC)的患病率及其对心血管事件和死亡率的预后作用,但结果存在争议。本荟萃分析旨在更准确地评估 CKD 患者 CAC 的患病率及其与心血管事件和死亡率的关系。
通过在 PubMed、Embase 和 Web of Science 上进行多次搜索策略,从成立之初到 2018 年 7 月确定并评估了相关文献。纳入了报告 CAC 患病率的横断面或队列(基线数据)研究。从合格研究中提取的数据用于计算效应估计值(ES)和 95%置信区间(95%CI)。我们在数据库中搜索了探讨 CKD 患者基线 CAC 与随后心血管或全因死亡率风险的观察性研究。
荟萃分析纳入了 47 项研究;其中 38 项研究纳入了 CAC 患病率的最终分析。在随机效应模型中,CAC 的总体患病率为 60%(95%CI 53-68%)。与 CAC 得分最低的患者相比,CAC 得分最高的患者全因死亡率(风险比 [HR] 3.44;95%CI 2.40-4.94)、心血管死亡率(HR 3.87;95%CI 2.06-7.26)和心血管事件(HR 2.09;95%CI 1.19-3.67)的风险均增加。
CAC 的总体患病率很高。CAC 与 CKD 患者的全因和心血管死亡率风险以及心血管事件独立相关。鉴于存在高度异质性,仍需要更大的临床试验。